Mallinckrodt, page-20

@4Seasons : Thanks for a posting this. Here is the actual 8-K filed today, 01/27/2016:
http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=251847&fid=14776623

"The total consideration of approximately $690 million (before tax) consists of approximately $574 million of up-front consideration, the assumption of approximately $39 million of long-term obligations, and approximately $77 million of contingent consideration."
“The divestiture of our Nuclear Imaging business is another important step toward the evolution of our portfolio,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt."

The "evolution of our portfolio" Mark Trudeau is talking about is the push toward getting less reliant on Mallinckrodt's pain killer and generic drugs market, as evidenced by their recent acquisition of regen med co Stratatech and of course the negotiation agreement with Mesoblast. MNK is very progressive.

Also, here's the 10-K dated 11/29/2016 where they clearly state that, on page 57, though they have a $500 million revolving credit facility, they have not used it:
http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=251847&fid=14691294
"In addition to the borrowing capacity under our receivable securitization program, we have a $500.0 million revolving credit facility. At September 30, 2016, we were not utilizing our revolving credit facility. As such there was $500.0 million of borrowing capacity under our revolving credit facility."

MNK knows their stuff and as I said in an earlier post, they can easily shell out the big bucks to Mesoblast to get their share of the LBP and GvHD markets.